Kiora Pharmaceuticals, Inc.

Report azionario NasdaqCM:KPRX

Capitalizzazione di mercato: US$12.0m

Kiora Pharmaceuticals Gestione

Criteri Gestione verificati 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Brian Strem

Amministratore delegato

US$971.7k

Compenso totale

Percentuale dello stipendio del CEO59.91%
Mandato del CEO4.8yrs
Proprietà del CEO1.4%
Durata media del managementNessun dato
Durata media del Consiglio di amministrazione4.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • May 21

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

Shareholders appeared to be happy with Kiora Pharmaceuticals, Inc.'s ( NASDAQ:KPRX ) solid earnings report last week...
Seeking Alpha • Oct 13

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Kiora Pharmaceuticals (NASDAQ:KPRX) has received a letter from Nasdaq on October 12, 2022 informing the company that it has regained compliance with the minimum bid price requirement. Kiora was previously notified by Nasdaq on February 23, 2022 that it was not in compliance with the minimum bid price rule.
Seeking Alpha • Sep 26

Kiora Pharma announces 1-for-40 reverse stock split

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), a biotech focused on treatments for eye disorders, announced Monday that the company’s shareholders authorized a reverse stock split of the common stock. Accordingly, the KPRX board has approved a decision to implement a reverse stock split of one share of common stock for every 40 shares, and the company shares will begin trading on Nasdaq on a split-adjusted basis on Sep. 27. KPRX shares added ~10% pre-market after the announcement. The reverse stock split is expected to reduce KPRX’s total outstanding common shares to ~1.1M with no impact on authorized shares and par value which will remain at 50M and $0.01, respectively. Kiora (KPRX) shares have plunged ~90% over the past 12 months underperforming the broader maker, as shown in this graph.
Seeking Alpha • Aug 12

Kiora Pharmaceuticals reports 1H results

Kiora Pharmaceuticals press release (NASDAQ:KPRX): 1H Net loss for the first half of 2022 was $6.0 million compared to $4.6 million for the first half of 2021. Cash and cash equivalents were $2.4 million as of June 30, 2022 with $1.1 million in prepaid expenses for research and development activities. Subsequent to the end of the first half, Kiora raised an additional $5.3 million in net proceeds from a public offering Shares +8.8% PM.
Seeking Alpha • Jul 28

Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing

Kiora Pharmaceuticals (NASDAQ:KPRX) said it was granted a U.S. patent covering hydrogel-based sustained release platforms, including KIO-201, which helps in controlled release of antibiotics to treat eye diseases. The Salt Lake City-based company added that the patent — No. 11,376,214 — relates to non-blurring, antibiotic-containing hydrogel compositions which have an extended contact time on the eye and have potential to improve the health of the ocular surface for accelerated wound healing. Kiora noted that KIO-201 is a chemically modified form of the natural polymer hyaluronic acid, formulated as an eye drop aimed to accelerate natural corneal wound healing. "In addition to potentially repairing corneal wounds as a standalone treatment, we see opportunities to employ our technology in combination with antibiotics to further accelerate wound healing and reduce post-surgical complications, including infections," said Kiora President and CEO Brian Strem.
Seeking Alpha • Jul 22

Kiora Pharmaceuticals prices $5.2M underwritten public offering

Kiora Pharmaceuticals (NASDAQ:KPRX) prices an underwritten public offering for gross proceeds of ~$5.2M prior to deducting underwriting discounts and commissions and offering expenses. Underwriters' have a 45-day option to purchase up to ~3.93M additional shares. Closing expected to take place on or about July 26, 2022.
Seeking Alpha • Jul 05

Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201

Kiora Pharmaceuticals (NASDAQ:KPRX) said it enrolled the first patient as a part of a phase 2 trial of its eye drops KIO-201 to treat patients with Persistent Corneal Epithelial Defect (PCED). PCED is a rare ocular surface condition characterized by non-healing wounds on the eye surface. KIO-201 is a chemically modified form of the natural polymer hyaluronic acid aimed to accelerate natural corneal wound healing, according to the company's July 5 press release. The study will enroll 10 patients who will be evaluated at 28 days after receiving KIO-201 six times daily. The trial's goals are to evaluate safety and tolerability︎, and the percentage of patients with corneal healing and the associated time to healing.

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Brian Strem rispetto agli utili di Kiora Pharmaceuticals?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$11m

Dec 31 2025US$972kUS$582k

-US$11m

Sep 30 2025n/an/a

-US$9m

Jun 30 2025n/an/a

-US$12m

Mar 31 2025n/an/a

-US$12m

Dec 31 2024US$955kUS$490k

US$4m

Sep 30 2024n/an/a

US$6m

Jun 30 2024n/an/a

US$3m

Mar 31 2024n/an/a

US$2m

Dec 31 2023US$805kUS$416k

-US$13m

Sep 30 2023n/an/a

-US$13m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$12m

Dec 31 2022US$714kUS$400k

-US$14m

Sep 30 2022n/an/a

-US$17m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$659kUS$169k

-US$14m

Compensazione vs Mercato: La retribuzione totale di Brian ($USD 971.70K ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 624.15K ).

Compensazione vs guadagni: La retribuzione di Brian è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Brian Strem (45 yo)

4.8yrs
Mandato
US$971,696
Compensazione

Dr. Brian M. Strem, Ph D., is Co-Founder and Director at Okogen, Inc. He served as Principal Financial and Accounting Officer of Kiora Pharmaceuticals, Inc. since June 16, 2022. He serves as President, Dir...

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Brian Strem
President4.8yrsUS$971.70k1.37%
$ 163.9k
Lisa Walters-Hoffert
Independent Director1.8yrsUS$131.82k0.028%
$ 3.4k
Praveen Tyle
Independent Chairman of the Board17.9yrsUS$189.91k0.11%
$ 13.5k
Carmine Stengone
Independent Director2.8yrsUS$122.44k0.028%
$ 3.4k
Aron Shapiro
Director5.1yrsUS$103.69k0.068%
$ 8.1k
Allen Ho
Member of Scientific Advisory Boardno dataNessun datoNessun dato
David Hollander
Independent Director4.4yrsUS$113.69k0%
$ 0
Mark Pennesi
Member of Scientific Advisory Board3.1yrsNessun datoNessun dato
Roger Goldberg
Member of Scientific Advisory Board1.9yrsNessun datoNessun dato
Erin Parsons
Non-Employee Independent Director4.3yrsUS$128.69k0.12%
$ 14.2k
Christine Kay
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Charlie Wykoff
Member of Scientific Advisory Boardno dataNessun datoNessun dato
4.3yrs
Durata media
49yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di KPRX sono considerati esperti (durata media dell'incarico 4.3 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/27 23:49
Prezzo dell'azione a fine giornata2026/05/27 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Kiora Pharmaceuticals, Inc. è coperta da 2 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Keay NakaeChardan Capital Markets, LLC
Michael OkunewitchMaxim Group